Genentech/IDEC collaborating on B-cell lymphoma, leukemia with IDEC's anti-CD20 monoclonal antibody.
Executive Summary
GENENTECH/IDEC ANTI-CD20 MAb FOR B-CELL LYMPHOMA 39424COLLABORATION expects to have IDEC's anti-CD 20 monoclonal antibody, IDEC-C2B8, in Phase III clinical trials by mid-1995 for non-Hodgkin's B-cell lymphomas (NHL), the companies said jointly March 16. Genentech and IDEC are planning additional studies for the primary indication, as well as for other B-cell cancers, such as intermediate-grade NHL and chronic lymphocytic leukemia, Genentech said.